Literature DB >> 29241142

Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group.

Peter Rieckmann1, Diego Centonze2, Irina Elovaara3, Gavin Giovannoni4, Eva Havrdová5, Jurg Kesselring6, Gisela Kobelt7, Dawn Langdon8, Sarah A Morrow9, Celia Oreja-Guevara10, Sven Schippling11, Christoph Thalheim12, Heidi Thompson13, Patrick Vermersch14, Karen Aston15, Birgit Bauer12, Christy Demory16, Maria Paz Giambastiani17, Jana Hlavacova18, Jocelyne Nouvet-Gire19, George Pepper20, Maija Pontaga21, Emma Rogan12, Chrystal Rogalski22, Pieter van Galen12, Ali-Frédéric Ben-Amor23.   

Abstract

BACKGROUND: Patient engagement is vital in multiple sclerosis (MS) in order to optimise outcomes for patients, society and healthcare systems. It is essential to involve all stakeholders in potential solutions, working in a multidisciplinary way to ensure that people with MS (PwMS) are included in shared decision-making and disease management. To start this process, a collaborative, open environment between PwMS and healthcare professionals (HCPs) is required so that similarities and disparities in the perception of key areas in patient care and unmet needs can be identified. With this patient-centred approach in mind, in 2016 the MS in the 21st Century Steering Group formed a unique collaboration to include PwMS in the Steering Group to provide a platform for the patient voice.
METHODS: The MS in the 21st Century initiative set out to foster engagement through a series of open-forum joint workshops. The aims of these workshops were: to identify similarities and disparities in the perception and prioritisation in three key areas (unmet needs, the treatment burden in MS, and factors that impact patient engagement), and to provide practical advice on how the gaps in perception and understanding in these key areas could be bridged.
RESULTS: Combined practical advice and direction are provided here as eight actions: 1. Improve communication to raise the quality of HCP-patient interaction and optimise the limited time available for consultations. 2. Heighten the awareness of 'hidden' disease symptoms and how these can be managed. 3. Improve the dialogue surrounding the benefit versus risk issues of therapies to help patients become fully informed and active participants in their healthcare decisions. 4. Provide accurate, lucid information in an easily accessible format from reliable sources. 5. Encourage HCPs and multidisciplinary teams to acquire and share new knowledge and information among their teams and with PwMS. 6. Foster greater understanding and awareness of challenges faced by PwMS and HCPs in treating MS. 7. Collaborate to develop local education, communication and patient-engagement initiatives. 8. Motivate PwMS to become advocates for self-management in MS care.
CONCLUSION: Our study of PwMS and HCPs in the MS in the 21st Century initiative has highlighted eight practical actions. These actions identify how differences and gaps in unmet needs, treatment burden, and patient engagement between PwMS and HCPs can be bridged to improve MS disease management. Of particular interest now are patient-centred educational resources that can be used during time-limited consultations to enhance understanding of disease and improve communication. Actively bridging these gaps in a joint approach enables PwMS to take part in shared decision-making; with improved communication and reliable information, patients can make informed decisions with their HCPs, as part of their own personalised disease management.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Burden of treatment; Communication; Education; Shared decision-making; Unmet needs

Mesh:

Year:  2017        PMID: 29241142     DOI: 10.1016/j.msard.2017.11.013

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  22 in total

1.  Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis.

Authors:  Natalie A Schwehr; Karen M Kuntz; Mary Butler; Eva A Enns; Nathan D Shippee; Elaine Kingwell; Helen Tremlett; Adam F Carpenter
Journal:  Mult Scler       Date:  2019-07-29       Impact factor: 6.312

2.  The 27-Item Multiple Sclerosis Quality of Life Questionnaire: A New Brief Measure Including Treatment Burden and Work Life.

Authors:  Helen Beckmann; Christoph Heesen; Matthias Augustin; Christine Blome
Journal:  Int J MS Care       Date:  2021-12-07

Review 3.  A Targeted Literature Search and Phenomenological Review of Perspectives of People with Multiple Sclerosis and Healthcare Professionals of the Immunology of Disease-Modifying Therapies.

Authors:  Jeri Burtchell; Daisy Clemmons; Joann Clemmons; Tim Sabutis; Adeline Rosenberg; Jennifer Graves; Michael L Sweeney; John Kramer; Marina Ziehn; Brandon Brown; Jamie L Weiss; Ahmed Z Obeidat
Journal:  Neurol Ther       Date:  2022-05-24

4.  Case Report: Fingolimod and Cryptococcosis: Collision of Immunomodulation with Infectious Disease.

Authors:  Rohini D Samudralwar; Andrej Spec; Anne H Cross
Journal:  Int J MS Care       Date:  2019 Nov-Dec

5.  Assessing Stigma in Multiple Sclerosis: Psychometric Properties of the Eight-Item Stigma Scale for Chronic Illness (SSCI-8).

Authors:  Javier Ballesteros; María L Martínez-Ginés; Jose M García-Domínguez; Lucía Forero; Daniel Prefasi; Jorge Maurino
Journal:  Int J MS Care       Date:  2019 Sep-Oct

6.  Impact of Shared Decision Making on Disease-Modifying Drug Adherence in Multiple Sclerosis.

Authors:  Aliza Ben-Zacharia; Meagan Adamson; Allison Boyd; Paula Hardeman; Jennifer Smrtka; Bryan Walker; Tracy Walker
Journal:  Int J MS Care       Date:  2018 Nov-Dec

7.  Advance care planning in progressive neurological diseases: lessons from ALS.

Authors:  Antje A Seeber; A Jeannette Pols; Albert Hijdra; Hepke F Grupstra; Dick L Willems; Marianne de Visser
Journal:  BMC Palliat Care       Date:  2019-06-13       Impact factor: 3.234

8.  Research-to-Practice Gaps in Multiple Sclerosis Care for Patients with Subjective Cognitive, Mental Health, and Psychosocial Concerns in a Canadian Center.

Authors:  Lisa A S Walker; Courtney Gardner; Mark S Freedman; Heather MacLean; Carolina Rush; Marjorie Bowman
Journal:  Int J MS Care       Date:  2019 Nov-Dec

9.  Measuring burden in caregivers of people with multiple sclerosis: psychometric properties of the CSI questionnaire.

Authors:  Jose M García-Domínguez; María L Martínez-Ginés; Olga Carmona; Ana B Caminero; Daniel Prefasi; Jorge Maurino; Javier Ballesteros
Journal:  Patient Prefer Adherence       Date:  2019-01-09       Impact factor: 2.711

10.  Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration.

Authors:  Barbara Willekens; Silvia Presas-Rodríguez; Nathalie Cools; Cristina Ramo-Tello; M J Mansilla; Judith Derdelinckx; Wai-Ping Lee; Griet Nijs; Maxime De Laere; Inez Wens; Patrick Cras; Paul Parizel; Wim Van Hecke; Annemie Ribbens; Thibo Billiet; Geert Adams; Marie-Madeleine Couttenye; Juan Navarro-Barriuso; Aina Teniente-Serra; Bibiana Quirant-Sánchez; Ascensión Lopez-Diaz de Cerio; Susana Inogés; Felipe Prosper; Anke Kip; Herman Verheij; Catharina C Gross; Heinz Wiendl; Marieke Sm Van Ham; Anja Ten Brinke; Ana Maria Barriocanal; Anna Massuet-Vilamajó; Niel Hens; Zwi Berneman; Eva Martínez-Cáceres
Journal:  BMJ Open       Date:  2019-09-09       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.